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permitted to continue adopting regula-
tions which favor the sole practitioner
over the optometry chain/franchise.
Optometry chains will likely push for
state legislation to loosen the restrictions
on corporate optometry.
RECENT MEETINGS:
At its August 13 meeting, the Board
discussed a draft legislative proposal to
increase license and examination fees to
cover the costs of these operations; cur-
rently, the fees cover one-fourth of the
costs. The Board also discussed a pro-
posal to regulate the retention of opto-
metric records; currently, no statute
requires the retention of optometric
records.
The Board discussed the initiation of
an educational program to control the
practice of optometry by unlicensed
individuals. The Board indicated con-
cern about optometric students who
begin working in an optometry practice
before receiving a license. Traditional
enforcement has not been effective in
curtailing unlicensed practice. The
Board therefore decided to issue a mem-
orandum to optometrists reminding them
that individuals who have not yet
received a license may not practice
optometry, even if supervised by a
licensed optometrist.
The Board's legal counsel issued a
clarification on the practice of optometry
in rest homes. Mobile practice is prohib-
ited; however, an optometrist may make
a house call to his/her own immobile
patient.
The Board has completed a consumer
pamphlet; however, as of its August 13
meeting, the Board had not yet found
funds for publication. The Board expects
to publish a newsletter to it own




Executive Officer: Patricia Harris
(916) 445-5014
Pursuant to Business and Professions
Code section 4000 et seq., the Board of
Pharmacy grants licenses and permits to
pharmacists, pharmacies, drug manufac-
turers, wholesalers and sellers of hypo-
dermic needles. It regulates all sales of
dangerous drugs, controlled substances
and poisons. The Board is authorized to
adopt regulations, which are codified in
Chapter 17, Title 16 of the California
Code of Regulations (CCR). To enforce
its regulations, the Board employs full-
time inspectors who investigate accusa-
tions and complaints received by the
Board. Investigations may be conducted
openly or covertly as the situation
demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized
by law to suspend or revoke licenses or
permits for a variety of reasons, includ-
ing professional misconduct and any acts
substantially related to the practice of
pharmacy.
The Board consists of ten members,
three of whom are public. The remaining
members are pharmacists, five of whom
must be active practitioners. All are
appointed for four-year terms.
At its May 30 meeting, the Board
announced that Patricia Harris has been
selected as its new Executive Officer.
MAJOR PROJECTS:
Investigation of Revenue Enhance-
ment Programs Between Physicians and
Home IV Providers. The Board has
appointed a special committee to investi-
gate the financial relationships between
physicians and home infusion compa-
nies. Although home infusion companies
are not specifically licensed by any state
agency, these relatively new service
companies contract with pharmacists, as
well as other licensed professionals, to
provide in-home intravenous (IV) thera-
py to specified patients. Only a pharma-
cist may supply medications to IV
patients on an ongoing basis; thus, the
pharmacist is an integral part of the
home IV therapy process.
It has come to the attention of the
Board that various "revenue enhance-
ment" or kickback schemes exist
between referring physicians and home
infusion companies. Business and Pro-
fessions Code sections 650 and 651 pro-
hibit compensation or financial induce-
ments to physicians for referrals, unless
certain criteria are met. Further, the U.S.
Inspector General is proposing various
"safe harbor" regulations, which specify
the types of financial arrangements
which are permissible without fear of
kickback prosecution. However, based
on concerns expressed by pharmacists
participating the home infusion industry,
the Board believes that certain "revenue
enhancement programs" amount to kick-
back violations.
The three most common financial
arrangements known to exist between
physicians and infusion companies are
as follows: (1) the infusion company is a
limited partnership in which physicians
buy shares as limited partners and share
in the profits; (2) a joint venture opera-
tion is created, which includes various
physicians as members of the joint ven-
ture; the physician contributes little to
the initial capitalization of the company,
but shares in a periodic division of the
profits; and (3) the patient's physician
acts as a "consultant" without ever actu-
ally visiting the patient at home. The
infusion company then provides the
medication and bills the patient or the
patient's insurance company. However,
payment goes directly to the physician,
who deducts up to 30% as a "consulting
fee" and forwards the remainder to the
infusion company. Much concern has
been raised over whether any legitimate
services are rendered by a physician as a
consultant, particularly when the physi-
cian never actually visits the patient per-
sonally for these "consulting" services.
Under current hospital practices, the
physician must personally visit the
patient in order to be financially com-
pensated, even if the physician is super-
vising the treatment. The home infusion
situation is comparable to the hospital in
terms of the service being rendered and
the standards for compensation.
The Board of Pharmacy's major con-
cern is that these financial relationships
are not in the best interest of the patient.
When there is a direct financial benefit at
stake, the physician may be less inclined
to prescribe an equally appropriate thera-
py which would cost less to the patient.
Due to the rapid increase in the home IV
industry in recent years, the Board is
concerned that many patients are receiv-
ing home IV antibiotics when oral
antibiotics would be appropriate. The
Board's special committee has identified
three major areas of focus for its investi-
gation: (1) Is there any harm to the
patient? (2) Are these practices in the
best interest of patient care? (3) Do they
interfere with freedom of choice in
selecting health care?
In addition, the committee will
address the following issues:
-examination of section 650 of the
Business and Professions Code for inter-
pretation and possible amendment, and
review of the proposed "safe harbor"
regulations;
-clarification of existing laws that
regulate the home IV provider industry
(including proposed regulations that will
be submitted to the Department of
Health Services for the licensure of
Home Health Agency/Home IV Drug
Therapy Providers);
-identification of legitimate services
and financial arrangements, including a
focus on the following: (a) impact on
patient care, (b) review of existing reim-
bursement enhancement programs and
clarification of known types of arrange-
ments, (c) identification of legitimate
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services for which doctors may be reim-
bursed in the home IV care area, (d) pro-
hibition of reimbursement programs
which provide payment for indirect
physician services, and (e) limitations on
the number of physicians who may serve
on advisory boards, and/or a requirement
of membership from other health profes-
sions;
-consideration of how the Medical
Board of California will enforce the
laws; and
-creation of separate types of pharma-
cy licenses.
The committee met on September 27
and planned to meet again on November
27. At the September meeting, the com-
mittee received input from pharmacists
as well as members of other state boards,
including the Medical Board and the
Board of Registered Nursing. The Board
would also like input from the insurance
industry.
Pharmacist Shortage. The Board is
concerned over an apparent shortage of
pharmacists in California and, at the
request of the California Retailers Asso-
ciation (CRA), has established a sub-
committee for the purpose of examining
possible solutions. The Board does not
grant license reciprocity to pharmacists
licensed in other states, which CRA
believes discourages out-of-state phar-
macists from working in California.
CRA requested that the Board consider
the following options to address the
shortage: administration of the National
Association of Boards of Pharmacy
Licensing Exam (NABPLEX), adminis-
tration of a third California exam each
year, continued efforts to dispel the myth
that a doctoral degree is required in Cali-
fornia for a pharmacy license, and the
issuance of a "provisional" license for
approximately one year.
Designation of Pharmacist-In-
Charge. At its October 3 meeting, the
Board was scheduled to hold a public
hearing on the proposed adoption of new
section 1709.1, Chapter 17, Title 16 of
the CCR, regarding designation of a
pharmacist-in-charge at each pharmacy.
Under existing regulations, a pharmacy
is required to have a pharmacist-in-
charge; however, the regulations do not
specifically limit the number of pharma-
cies that a single pharmacist-in-charge
may simultaneously oversee, nor do they
specifically authorize the designation of
an interim pharmacist-in-charge while a
permanent pharmacist-in-charge is being
designated or recruited.
This proposal would require each
pharmacy to designate a pharmacist-in-
charge who shall have responsibility for
the daily operation of that pharmacy, and
who shall be the permanent pharmacist-
in-charge of only that single pharmacy.
The proposal would also authorize the
designation of an interim pharmacist-in-
charge for up to 120 days, during which
time a permanent pharmacist-in-charge
is being designated. Under proposal, the
Board may examine the involvement of
the interim pharmacist-in-charge in the
day-to-day activities of the pharmacy,
and review a pharmacy's efforts to
obtain a permanent pharmacist-in-
charge.
According to the Board, the purpose
of the proposal is to assure that adequate
records of the daily operation of the
pharmacy are maintained. Presumably, a
pharmacist-in-charge with little knowl-
edge of day-to-day operations in a single
pharmacy is less likely to keep adequate
records which are necessary to regulato-
ry agencies to assure compliance with
state and federal laws.
Processing Times for Applications
and Registrations. Pursuant to the Per-
mit Reform Act of 1981, Government
Code section 15374 et seq., the Board
proposes to adopt changes to section
1706.1, Chapter 17, Title 16 of the CCR.
The changes would set forth the Board's
actual past processing time of applica-
tions for licensure or registration, and
provide the maximum time periods for
notifying an applicant whether an appli-
cation is complete (thirty days in most
cases) and for issuing or denying a
license or registration (sixty days in most
cases). The Board was scheduled to hold
a public hearing on this proposed regula-
tory change on October 3.
Other Regulatory Changes. The fol-
lowing is a status update on numerous
regulatory changes considered and
approved by the Board in recent months
(see CRLR Vol. 10, Nos. 2 & 3
(Spring/Summer 1990) pp. 114-15; Vol.
10, No. I (Winter 1990) p. 90; and Vol.
9, No. 4 (Fall 1989) p. 75 for back-
ground information on these changes):
-Ancillary Personnel. On March 1,
OAL rejected for a second time the
Board's amendment to section 1717,
which specifies the tasks which may be
performed by an unlicensed person
under the supervision of a licensed phar-
macist. OAL primarily rejected this reg-
ulatory change on grounds that it is
inconsistent with numerous sections of
the Business and Professions Code,
which specify that only a licensed phar-
macist may "dispense" drugs. OAL has
trouble with several "packaging tasks"
which the new rule would authorize unli-
censed personnel to perform; it believes
that these "packaging tasks" may be part
of "dispensing" and therefore non-dele-
gable to persons who are not registered
pharmacists or statutory exemptees. The
Board strongly disagrees with OAL's
interpretation and appealed it to the Gov-
ernor's office.
On September 19, the Governor's
office referred the matter back to OAL
for reconsideration. Specifically, the
Governor's office stated that "the sole
question is whether or not the Board of
Pharmacy has the legal authority to
accomplish its intended goal by way of
regulation rather than by a law change
through legislation." The Governor's
office expressly instructed OAL to con-
sider materials submitted by the Board
concerning federal regulations permit-
ting unlicensed assistants to perform
specified tasks. The Governor's office
gave the Board thirty days in which to
forward to OAL any additional informa-
tion on the federal regulations; and OAL
thirty days from the receipt of that infor-
mation (or until November 18, whichev-
er is sooner) to render its decision on the
matter.
-Oral Consultation. On August 10,
OAL approved the Board's adoption of
new section 1707.1, which requires
pharmacists to maintain patient medica-
tion profiles for all ongoing patient-con-
sumers, and to provide an oral consulta-
tion to each patient or patient's agent,
with specified exceptions.
-English Proficiency Examination.
On April 18, OAL rejected the Board's
amendment of section 1719, which
would require that candidates for licen-
sure who have been non-U.S. residents
for more than ten years to take and pass
the Test of Spoken English in addition to
satisfying all other licensure require-
ments. The Board requested and
received a 120-day extension from OAL
for resubmitting this regulation, and
planned to refile it in November.
-Preprinted Prescription Pads. At is
May 30 meeting, the Board held a public
hearing on proposed regulatory section
1717.3, which would define a "preprint-
ed, multiple check-off prescription
blank" and the permissible ways in
which these may be used. The Board
approved the proposal, which would
prohibit pharmacists from (1) dispensing
controlled substances pursuant to such
preprinted blanks; and (2) dispensing
more than one dangerous drug from such
a preprinted blank. This proposal still
awaits review and approval by OAL.
Attorney General's Opinion. At its
May 30 meeting, the Board expressed its
dissatisfaction with Attorney General's
Opinion No. 89-1101, regarding inter-
pretation of section 4046(c)(1) of the
Business and Professions Code. (See
CRLR Vol. 10, Nos. 2 & 3 (Spring/Sum-
mer 1990) p. 115 for a summary of this
opinion.) The Board will seek reconsid-
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eration of the opinion and move ahead
with a regulation to clarify the term "rea-
sonable quantity."
LEGISLATION:
SB 2815 (Roberti), as amended
August 22, would have required the
Department of Aging, in consultation
with the Board of Pharmacy, to develop
and distribute a brochure for the purpose
of helping prevent the misuse of medica-
tions, increasing the awareness of the
problems associated with the use of mul-
tiple medications, and increasing com-
pliance with instructions for medication
use by older persons. The bill also would
have required pharmacists providing a
prescription medication to an older per-
son to give that person a copy of the
brochure, discuss the effects of the medi-
cation with the person, and contact the
prescribing physician if he/she believes
a medication is causing an adverse reac-
tion or adverse drug interaction in the
person. This bill was vetoed by the Gov-
ernor on September 29.
AB 3924 (Cannella), as amended
August 15, extends the exemption from
home health agency licensing require-
ments, until January 1, 1992, for a
licensed pharmacy engaged in provid-
ing, pursuant to the order of a physician,
parenteral or enteral therapies adminis-
tered by a licensed registered nurse
employed, or whose services are
arranged for, by the pharmacy. This bill
was signed by the Governor on Septem-
ber II (Chapter 761, Statutes of 1990).
The following is a status report on
bills discussed in CRLR Vol. 10, Nos. 2
& 3 (Spring/Summer 1990) at pages
115-16:
AB 4168 (Hunter), as amended
August 17, would have specified that
products listed as "Code A" in a speci-
fied publication issued by the U.S.
Department of Health and Human Ser-
vices may be substituted by pharmacists
for the generic equivalent; and that if the
drug product is designated as "Code B"
in that publication, the pharmacist is
prohibited from substituting for the
product unless he/she consults with the
prescribing physician. This bill was
vetoed by the Governor on September
30.
SB 736 (Marks), as amended August
27, would have required the state
Department of Health Services (DHS) to
approve senior citizen medical education
programs from July 1, 1991, through
June 30, 1992, in up to six local health
jurisdictions. The bill was vetoed by the
Governor on September 21.
AB 3276 (Bronzan), as amended July
3, requires a pharmacist to provide a
label or enclosure with the drug contain-
er whenever a prescribed drug has not
previously been dispensed to the patient,
or whenever the prescribed drug has
been dispensed in a different dosage,
form, strength, or with different written
directions. This bill was signed by the
Governor on September 8 (Chapter 641,
Statutes of 1990).
AB 3975 (Margolin), as amended
August 17, would have required the
Board to designate a statewide drug
information center to provide direct tele-
phone assistance or referral to appropri-
ate health care providers for any person
desiring information relating to prescrip-
tion drugs. This bill was vetoed by the
Governor on September 27.
AB 4106 (Polanco), as amended July
9, provides that a person exempt from
the Pharmacy Licensing Law must be
present any time a person is seeking a
fitting or consultation on a medical
device, except that an exemptee need not
be present if the dangerous devices are
stored in a secure locked area, as speci-
fied. This bill was signed by the Gover-
nor on September 18 (Chapter 1074,
Statues of 1990).
SB 1829 (Watson) would have autho-
rized DHS to implement a specified pilot
project in San Francisco under which
San Francisco's health officer would be
required to develop new, innovative pro-
grams or undertake new measures to pre-
vent the further spread of certain dis-
eases. This bill died in the Senate
inactive file.
AB 2713 (Moore), as amended
August 21, requires manufacturers of
nonprescription drugs sold in California
to permit the modification of the labeling
of nonprescription drugs to maximize
the readability and clarity of label infor-
mation, in both the cognitive and visual
sense. This bill was signed by the Gover-
nor on September 12 (Chapter 839,
Statutes of 1990).
AB 2827 (Roberti), as amended
August 7, requires the Board to encour-
age every licensed pharmacist to take a
course in geriatric pharmacology as part
of his/her continuing education require-
ments. This bill was signed by the Gov-
ernor on September 29 (Chapter 1539,
Statutes of 1990).
AB 1006 (Isenberg), as amended July
9, would have required a health care ser-
vice plan or nonprofit hospital service
plan to give notice to all pharmacy
providers of its intent to contract for
pharmacy services. This bill was vetoed
by the Governor on September 26.
AB 1177 (Kelley) would have
required a pharmacist to inform a patient
either orally or in writing of the harmful
effects of a drug dispensed by prescrip-
tion, if the drug poses substantial risk
when taken in combination with other
prescribed drugs known by the pharma-
cist as having been dispensed to that
patient. This bill died in the Senate Busi-
ness and Professions Committee.
FUTURE MEETINGS:
January 30-31 in San Francisco.
March 20-21 in Los Angeles.
May 29-30 in Sacramento.
July 30-August I in Sacramento.
October 16-17 in Los Angeles.
BOARD OF REGISTRATION FOR
PROFESSIONAL ENGINEERS
AND LAND SURVEYORS
Executive Officer: Darlene Stroup
(916) 920-7466
The Board of Registration for
Professional Engineers and Land Sur-
veyors (PELS) regulates the practice of
engineering and land surveying through
its administration of the Professional
Engineers Act, sections 6700 through
6799 of the Business and Professions
Code, and the Professional Land Survey-
ors' Act, sections 8700 through 8805 of
the Business and Professions Code. The
Board's regulations are found in Chapter
5, Title 16 of the California Code of
Regulations (CCR).
The basic functions of the Board are
to conduct examinations, issue certifi-
cates, registrations, and/or licenses, and
appropriately channel complaints against
registrants/licensees. The Board is addi-
tionally empowered to suspend or
revoke registrations/licenses. The Board
considers the proposed decisions of
administrative law judges who hear
appeals of applicants who are denied a
registration/license, and those who have
had their registration/license suspended
or revoked for violations.
The Board consists of thirteen mem-
bers: seven public members, one
licensed land surveyor, four registered
Practice Act engineers and one Title Act
engineer. Eleven of the members are
appointed by the Governor for four-year
terms which expire on a staggered basis.
One public member is appointed by the
Speaker of the Assembly and one by the
Senate President pro Tempore.
The Board has established four stand-
ing committees and appoints other spe-
cial committees as needed. The four
standing committees are Administration,
Enforcement, Examination/Qualifica-
tions, and Legislation. The committees
function in an advisory capacity unless
specifically authorized to make binding
decisions by the Board.
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